Rare diseases

Antifibrotic agent slows progression of RA-ILD

Nintedanib slows the rate of decline in forced vital capacity (FVC) in patients with progressive fibrosing RA associated interstitial lung disease (RA-ILD), according to data presented at EULAR 2021. The subanalysis of the INBUILD trial comprised 89 patients with RA-ILD of...

Nintedanib slows the rate of decline in forced vital capacity (FVC) in patients with progressive fibrosing RA associated interstitial lung...
Psoriatic arthritis

EULAR 2021: Enthusiasm for FMT not matched by results in psoriatic arthritis

Faecal microbiota transplantation (FMT) offers no advantage for patients with active peripheral psoriatic arthritis. The findings challenge enthusiasm for a relationship between microbial dysbiosis and joint inflammation as per gut inflammation. The FLORA trial, presented at EULAR 2021, evaluated the effectiveness and...

Faecal microbiota transplantation (FMT) offers no advantage for patients with active peripheral psoriatic arthritis. The findings challenge enthusiasm for a relationship...